logo
Salesforce Inc. (CRM) is Attracting Investor Attention: Here is What You Should Know

Salesforce Inc. (CRM) is Attracting Investor Attention: Here is What You Should Know

Yahoo02-06-2025

Salesforce.com (CRM) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this customer-management software developer have returned -3.5% over the past month versus the Zacks S&P 500 composite's +6.1% change. The Zacks Computer - Software industry, to which Salesforce.com belongs, has gained 13.2% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Salesforce.com is expected to post earnings of $2.73 per share, indicating a change of +6.6% from the year-ago quarter. The Zacks Consensus Estimate has changed +4% over the last 30 days.
The consensus earnings estimate of $11.14 for the current fiscal year indicates a year-over-year change of +9.2%. This estimate has changed +1.3% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $12.36 indicates a change of +11% from what Salesforce.com is expected to report a year ago. Over the past month, the estimate has changed +0.2%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Salesforce.com.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Salesforce.com, the consensus sales estimate of $10.12 billion for the current quarter points to a year-over-year change of +8.5%. The $41.13 billion and $44.7 billion estimates for the current and next fiscal years indicate changes of +8.6% and +8.7%, respectively.
Salesforce.com reported revenues of $9.83 billion in the last reported quarter, representing a year-over-year change of +7.6%. EPS of $2.58 for the same period compares with $2.44 a year ago.
Compared to the Zacks Consensus Estimate of $9.74 billion, the reported revenues represent a surprise of +0.95%. The EPS surprise was +1.57%.
Over the last four quarters, Salesforce.com surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Salesforce.com is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Salesforce.com. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Salesforce Inc. (CRM) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Best stocks: Entertainment stocks are unlikely winners this year — One to watch if it can break $120
Best stocks: Entertainment stocks are unlikely winners this year — One to watch if it can break $120

CNBC

time23 minutes ago

  • CNBC

Best stocks: Entertainment stocks are unlikely winners this year — One to watch if it can break $120

(This is The Best Stocks in the Market , brought to you by Josh Brown and Sean Russo of Ritholtz Wealth Management.) Josh — Sometimes I'm surprised by what's working in the market. If I had to guess, I probably would not have picked entertainment-related companies to be among the best industry groups in the S & P 500 on a year-to-date basis and neither would you have. And that's despite the fact that we've been writing about Spotify and Netflix here an awful lot. Turns out there's more to the story than just those two tickers, as Sean will reveal. Within that group of names, Disney (DIS) popped onto our list as Wall Street begins to give the company more credit for its 125 million global Disney Plus subscribers, 12% market share in streaming video on demand (SVOD) and almost $3 billion in streaming revenue in the first quarter of this year. We'll show you the chart below, but first some Best Stocks stats: Sector Leaderboard As of 6/23/2025 morning, there are 115 names on The Best Stocks in the Market list Top Sector Ranking: Top Industries: Top 5 Best Stocks by Relative Strength: Sector Spotlight: Entertainment Sean — Within S & Ps classification, companies like Disney , Live Nation , and Roblox all land within the entertainment sector, which interestingly is not in the consumer discretionary sector, but is classified as communications. The lines between media, technology, and communication have blurred. From Netflix's growing streaming platform to Roblox's virtual worlds and Live Nation's global concert footprint, these platforms have become less cyclical. We highlighted this defensive trait in some of these stocks in our first piece for The Best Stocks in the Market. We aren't just seeing less volatility in these stocks — we're seeing growth. Just last week, Roblox hit a new all-time high for concurrent users with 25.8M players utilizing the platform at the same time. Nielsen just put out rankings and data for television inclusive of streaming platforms, and 50% of the top 10 best performing shows (ranked by viewers over a 35 day period) came from Netflix. The entertainment industry has done quite well despite the increased recession risk. Looking at every entertainment-classified stock in the S & P 500 (there are 10), the median year-to-date return is 17.5%. The median return for a stock in the S & P 500 is less than 1%. Ninety percent of the entertainment industry within the S & P 500 is within 10% of a 52 week high, the only stock not within a 52 week high is Warner Brothers (WBD). Only 35% of the S & P 500 is within 10% of 52 week highs. We currently have 7 entertainment industry stocks on our list: Disney, Liberty Media , Live Nation, Netflix, Roblox, Spotify, and Take-Two Interactive . Disney makes the list This is a 5 year price chart for Disney: It has been a struggle for Disney, but the stock just rocketed off its early April lows. If the stock can meaningfully break out above that $120 level, there is a ton of room for the stock to run. Disney is dominating the box office thus far. Three of the top 5 best performing movies this year are Disney releases. Lilo & Stitch is the second best movie grossing $386M, Captain America: Brave New World is 4th taking in $200M, and Thunderbolts is in the 5th spot at $189.5M. This industry has quietly become one of the strongest performers in the S & P 500 this year. With user growth accelerating on platforms like Roblox, dominant streaming engagement from Netflix, and a resurgent box office led by Disney, this group is performing well in what has been a challenging environment for consumer-sensitive names. Risk management: Josh — Let's keep this one simple. The $120 level is resistance. You can see that clearly in the chart below. Each attempt to get above was smacked down as the sellers swamped the buyers. That will happen until it doesn't, and then look out. I'm showing you a longer term chart here because I want you to see the whole consolidation. I'd use the $100 level as my line in the sand. If it gets below there the momentum is dead — that's the market telling you to look for a better set-up. DISCLOSURES: (None) All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. INVESTING INVOLVES RISK. EXAMPLES OF ANALYSIS CONTAINED IN THIS ARTICLE ARE ONLY EXAMPLES. THE VIEWS AND OPINIONS EXPRESSED ARE THOSE OF THE CONTRIBUTORS AND DO NOT NECESSARILY REFLECT THE OFFICIAL POLICY OR POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC. JOSH BROWN IS THE CEO OF RITHOLTZ WEALTH MANAGEMENT AND MAY MAINTAIN A SECURITY POSITION IN THE SECURITIES DISCUSSED. ASSUMPTIONS MADE WITHIN THE ANALYSIS ARE NOT REFLECTIVE OF THE POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC" TO THE END OF OR OUR DISCLOSURE. Click here for the full disclaimer.

The Zacks Analyst Blog Highlights Meta, Palantir, Abbott Laboratories, SandRidge and CompX
The Zacks Analyst Blog Highlights Meta, Palantir, Abbott Laboratories, SandRidge and CompX

Yahoo

time34 minutes ago

  • Yahoo

The Zacks Analyst Blog Highlights Meta, Palantir, Abbott Laboratories, SandRidge and CompX

Chicago, IL – June 23, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Meta Platforms, Inc. META, Palantir Technologies Inc. PLTR, Abbott Laboratories ABT, SandRidge Energy, Inc. SD and CompX International Inc. CIX. The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc., Palantir Technologies Inc. and Abbott Laboratories, as well as two micro-cap stocks SandRidge Energy, Inc. and CompX International Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>> Ahead of Wall Street The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning. You can read today's AWS here >>> Pre-Markets Climb on Rate Cut Visibility Today's Featured Research Reports Meta Platforms' shares have outperformed the Zacks Internet - Software industry over the past year (+39.2% vs. +37.1%). The company is benefiting from steady user growth across all regions, particularly Asia Pacific. Increased engagement for its offerings like Instagram, WhatsApp, Messenger and Facebook has been a major growth driver. META has been leveraging AI to improve the potency of its offerings. These services currently reach more than 3.43 billion people daily. Meta Platforms' growing footprint among young adults, driven by improving recommendations, boosts its competitive prowess. AI usage is making it a popular name among advertisers. This is expected to drive top-line growth. Meta Platforms now expects to invest significantly more over the next few years in developing more advanced models and the largest AI services in the world. However, monetization of these AI services will take considerable time, which is a concern. (You can read the full research report on Meta Platforms here >>>) Shares of Palantir have outperformed the Zacks Internet - Software industry over the year-to-date period (+85% vs. +13%). The company's AI strategy, driven by Foundry, Gotham and AIP platforms, targets government and commercial sectors, enabling real-time insights and operational efficiency. Notable defense projects like Open DAGIR, and AIP boot camps for commercial clients boost customer acquisition. With $5.2 billion in cash, no debt and S&P 500 inclusion, Palantir enjoys strong liquidity, growing revenues and increased investor visibility. However, PLTR's reluctance to pay quarterly dividends is a minus for dividend-seeking investors. Intense competition from tech giants and rising costs amidst a rapidly evolving AI landscape and an elevated valuation also challenge its appeal. (You can read the full research report on Palantir here >>>) Abbott's shares have outperformed the Zacks Medical - Products industry over the past year (+27.8% vs. +8.9%). The company's pipeline is unlocking new growth opportunities, supporting the company's positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory. Alinity, the company's next-generation suite of systems, is a key driver in the core lab diagnostics business. Abbott is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales, beginning 2025. Within Nutrition, despite softness in the international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business. Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott's Diagnostics growth. Headwinds such as tough macro conditions and foreign exchange also adds to the worry. (You can read the full research report on Abbott here >>>) Shares of SandRidge Energy have outperformed the Zacks Oil and Gas - Integrated - U.S. industry over the year-to-date period (+5.3% vs. -1.6%). This microcap company with a market capitalization of $443.18 million has a debt-free balance sheet and $101.1 million cash position back strong self-funding capacity, and $13.6 million in free cash flow in Q1 2025. Adjusted EBITDA jumped 73% to $25.5 million on higher volumes and better gas prices, with gas now 49% of production. Since 2023, $158 million has been returned to shareholders via dividends and buybacks, with $70 million repurchase capacity remaining. Cherokee drilling supports reserve growth, but capital intensity and WTI/gas price volatility pose risks. Heavy back-half completions, cost inflation, and natural gas legacy underutilization limit efficiency. Large NOLs support tax sheltering but rely on consistent profits; Section 382 limits apply. Reserve quality hinges on Cherokee execution as legacy reserves decline. Commodity swings and execution missteps could pressure cash flow and returns despite strong capital discipline. (You can read the full research report on SandRidge Energy here >>>) CompX International's shares have outperformed the Zacks Office Supplies industry over the past year (+18.8% vs. -38%). This microcap company with a market capitalization of $293.43 million has first-quarter 2025 results highlighting resilient core operations and expanding profitability. Security Products maintained a stable gross margin (29.8%) despite OEM softness, supported by gains in government and healthcare markets. Marine Components delivered a 24% year-over-year sales increase and a structural margin uplift to 22.3%, driven by fixed cost leverage and a favorable product mix. The company-wide gross margin rose to 30.2%, fueling a 58% surge in operating income. Cash remained strong at $56.1 million, with no debt and improved inventory efficiency. However, risks include negative operating cash flow due to rising receivables, a 29% drop in interest income and tariff-driven raw material inflation. Continued OEM channel weakness and DSO expansion raise caution, but internal execution and margin tailwinds position CompX for an upside in 2025. (You can read the full research report on CompX International here >>>) Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report SandRidge Energy, Inc. (SD) : Free Stock Analysis Report CompX International Inc. (CIX) : Free Stock Analysis Report Palantir Technologies Inc. (PLTR) : Free Stock Analysis Report Meta Platforms, Inc. (META) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Top Stock Movers Now: Tesla, Hims & Hers, Wolfspeed, and More
Top Stock Movers Now: Tesla, Hims & Hers, Wolfspeed, and More

Yahoo

time43 minutes ago

  • Yahoo

Top Stock Movers Now: Tesla, Hims & Hers, Wolfspeed, and More

U.S. equities were higher at midday as concerns oil prices would spike because of the U.S. attack on Iran diminished. Northern Trust was reportedly approached by Bank of New York Mellon about a merger. Novo Nordisk ended an agreement with Hims & Hers that had allowed the telehealth firm to offer the Wegovy weight-loss drug to its customers.U.S. equities advanced at midday as oil prices declined on doubts the weekend U.S. military strikes against Iran and possible retaliation from Iran would disrupt supplies. The Dow Jones Industrial Average, S&P 500, and Nasdaq all gained. Tesla (TSLA) was the best-performing stock in the S&P 500 when CEO Elon Musk said the launch of the electric vehicle (EV) maker's robotaxi in Austin, Texas, was a success. Northern Trust (NTRS) shares jumped on a report the bank was approached by Bank of New York Mellon (BK), or BNY, about a possible merger. BNY shares fell. Shares of fintech firm Fiserv (FI) rose on a plan for a new stablecoin. U.S.-listed shares of Novo Nordisk (NVO) dropped when the drugmaker's new experimental obesity drug wasn't as effective in reducing weight as hoped. Meantime, Novo Nordisk ended its agreement with Hims & Hers Health (HIMS) allowing it to offer Wegovy to customers, sending shares of the telehealth firm plunging. Shares of struggling silicon carbide chipmaker Wolfspeed (WOLF) cratered when the company announced it had filed for Chapter 11 bankruptcy as it moved to restructure its debt with key lenders. Gold futures rose. The yield on the 10-year Treasury note slid. The U.S. dollar was up on the yen but lost ground to the euro and pound. Most major cryptocurrencies traded higher. Read the original article on Investopedia

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store